MedTrace Logo

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection

NCT00388167 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2009-05-13

No results posted yet for this study

Summary

We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive Aspergillosis (AI) in adults patients who are refractory to or intolerant of other therapies (i.e., amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).

Conditions

  • Candidiasis
  • Aspergillosis

Interventions

DRUG

Caspofungin

The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment

Sponsors & Collaborators

  • GTEI

    collaborator UNKNOWN

  • SEMICYUC

    collaborator UNKNOWN

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Miguel Angel Sanz, Dr · Hospital La Fe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2008-02-29

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388167 on ClinicalTrials.gov